US (NY): New platform launched for accelerated development of new hemp/cannabis varieties with commercially valuable traits

22nd Century Group has developed and launched a new technology platform that will enable the Company and its partners to quickly identify and incorporate commercially valuable traits of hemp/cannabis plants to create new, stable hemp/cannabis lines. "The platform incorporates a suite of proprietary molecular tools and a large library of genomic markers and gene-trait correlations," 22nd Century team explains. "The platform was developed in collaboration with researchers at KeyGene, a global leader in plant research involving high-value genetic traits and increased crop yields."

“This is a major breakthrough. Quickly and easily identifying the genes responsible for specific traits in a plant is a powerful tool for 22nd Century Group and the hemp/cannabis industry as a whole,” said James A. Mish, chief executive officer of 22nd Century Group. “That is why we are even now beginning discussions to license this platform to strategic partners to help them improve their plant breeding techniques and to optimize their hemp/cannabis cultivars. We continue to make great advancements through our partnership with KeyGene, and this newly developed molecular breeding platform has the potential to result in exponential growth for the Company’s revenues and create new value opportunities for our stakeholders, including shareholders.”

“Using traditional breeding techniques, it typically takes at least eight to ten years to develop new varieties of hemp/cannabis plants that consistently express important traits,” said Juan Sanchez Tamburrino, Ph.D., vice president of research and development at 22nd Century Group. “Our new molecular breeding platform can dramatically reduce our development time for new high-value varieties of hemp/cannabis and allows 22nd Century scientists to identify plant lines that carry high levels of major therapeutic cannabinoids, such as cannabidiol (CBD), cannabichromene (CBC), and other minor therapeutic cannabinoids, like cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV).”

Demonstrating how this technology can be used, 22nd Century and KeyGene scientists can now accelerate the selection of specific traits yielding novel cannabinoid profiles. For example, the team was able to select specific markers that predict the sex of hemp/cannabis plants with an astounding 99.6% accuracy.

Using this new breeding technology, 22nd Century has already characterized millions of high-value single nucleotide polymorphisms (SNPs). SNPs are molecular markers or guideposts within a plant’s genome that indicate important variations in Deoxyribonucleic acid (DNA) sequences. Targeting these newly identified SNPs, 22nd Century was able to locate and isolate specific sections of genetic code from genome assemblies present in the Company’s state-of-the-art hemp/cannabis bioinformatics database. 22nd Century’s bioinformatics database continues to grow and already contains hundreds of hemp/cannabis genomes and thousands expression datapoints across a wide array of hemp/cannabis varieties and phenotypes. The ability to identify specific genetic variations allows researchers to isolate high-value traits, like increased CBD or tetrahydrocannabinol (THC) production, and then introduce those traits in new plant lines using modern plant breeding techniques, including trait tracking using molecular marker profiles and the Company’s proprietary accelerated breeding pipeline.

For more information:
22nd Century Group
James Vail
8560 Main Street
Williamsville, NY 14221
P: 716-270-1523
F: 716-877-3064  

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Twitter Rss

© 2021

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber